Review article: The role of adipose tissue in uraemia-related insulin resistance

Nephrology

Volumn 13, Issue 7, 2008, Pages 622-628

  Manolescu, Bogdan ^a   Stoian, Irina ^a   Atanasiu, Valeriu ^a   Busu, Carmina ^a   Lupescu, Olivera ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adiponectin; IL 6; Insulin resistance; Leptin; Renal failure; Resistin

Indexed keywords

ADIPOCYTOKINE;

ADIPOSE TISSUE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; ENERGY EXPENDITURE; FOOD INTAKE; HOMEOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; LIPID METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; UREMIA;

EID: 54049130793     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01022.x     Document Type: Review

References (78)

1. Fruhbeck G, Salvador J. Role of adipocytokines in metabolism and disease. Nutr. Res. 2004 24 : 803 26.
2. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissue. Biochim. Biophys. Acta 2000 1500 : 88 96.
3. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J. Clin. Invest. 2005 115 : 1111 19.
4. Mohamed-Ali V, Flower L, Sethi J et al. Beta-adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 2001 86 : 5864 9.
5. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 2003 112 : 1785 8.
6. Axelsson J, Qureshi AR, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am. J. Clin. Nutr 2004 80 : 1222 9.
7. Stenvinkel P. Inflammation in end-stage renal disease - A fire that burns within. Contrib. Nephrol. 2005 149 : 185 99.
8. Considine RV. Weight regulation, leptin and growth hormone. Horm. Res. 1997 48 : 116 21.
9. Meyer C, Robson D, Rackovsky N, Nadkarni V, Gerich J. Role of the kidney in human leptin metabolism. Am. J. Physiol. Endocrinol. Metab. 1997 273 : E903 7.
10. Sharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997 51 : 1980 85.
11. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995 83 : 1263 71.
12. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int. 1998 54 : 1267 75.
13. Cumin F, Baum HP, Levens N. Mechanism of leptin removal from the circulation by the kidney. J. Endocrinol. 1997 155 : 577 85.
14. Kümpers P, Gueler F, Rong S et al. Leptin is a coactivator of TGF-beta in unilateral ureteral obstructive kidney disease. Am. J. Physiol. Renal Physiol. 2007 293 : F1355 62.
15. Stenvinkel P, Heimburger O, Lonngvist F. Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrol. Dial. Transplant. 1997 12 : 1321 5.
16. Wiecek A, Adamczak M, Chudek J. Adiponectin - An adipokine with unique metabolic properties. Nephrol. Dial. Transplant. 2007 22 : 981 8.
17. Wang Y, Xu LY, Lam KS, Lu G, Cooper GJ, Xu A. Proteomic characterization of human serum proteins associated with the fat-derived hormon adiponectin. Proteomics 2006 6 : 3862 70.
18. Yamauchi T, Kamon J, Ito J et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003 423 : 762 9.
19. Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M. Expanding role of AMPK in endocrinology. Trend. Endocrinol. Metab. 2006 17 : 205 15.
20. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med. 2002 8 : 1288 95.
21. Tomas E, Tsao TS, Saha AK et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 2002 99 : 16309 13.
22. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 2003 278 : 45021 5.
23. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J. Biol. Chem. 2004 279 : 28670 74.
24. Kobayashi H, Ouchi N, Kihara S et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res. 2004 94 : e27 e31.
25. Wu X, Mahadev K, Fuchsel L, Ouedraogo R, Xu S-S, Goldstein BJ. Adiponectin suppresses IkB kinase activation induced by tumor necrosis factor-α or high glucose in endothelial cells: Role of cAMP and AMP kinase signaling. Am. J. Physiol. Endocrinol. Metab. 2007 293 : E1836 44.
26. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/A CRP30. Nature Med. 2002 8 : 731 7.
27. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1Ra in human leukocytes. Biochem. Biophys. Res. Commun. 2004 323 : 630 35.
28. Fasshauer M, Kralisch S, Klier M et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2003 301 : 1045 50.
29. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004 114 : 1752 61.
30. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000 20 : 1595 9.
31. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003 361 : 226 8.
32. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002 13 : 134 41.
33. Ignacy W, Chudek J, Adamczak M et al. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease - A follow-up study. Nephron Clin. Pract. 2005 101 : c18 c24.
34. Guebre-Egziabher F, Bernhard G, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol. Dial. Transplant. 2005 20 : 129 34.
35. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J. Am. Soc. Nephrol. 2005 16 : 1091 8.
36. Iwashima Y, Horio T, Kumada M et al. Adiponectin and renal function, and risk of cardiovascular disease. Am. J. Cardiol. 2006 98 : 1603 8.
37. Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J. Am. Soc. Nephrol. 2006 17 : 2599 2606.
38. Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron 2001 89 : 348 9.
39. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol. Dial. Transplant. 2007 22 : 171 8.
40. Banerjee RR, Lazar MA. Dimerization of resistin and resistin-like molecules is determined bya single cysteine. J. Biol. Chem. 2001 276 : 25970 73.
41. Osawa H, Onuma H, Ochi M et al. SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem. Biophys. Res. Commun. 2005 335 : 596 602.
42. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am. J. Kidney Dis. 2003 42 : 62 6.
43. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001 409 : 307 12.
44. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006 69 : 596 604.
45. Filippidis G, Liakopoulos V, Mertens PR et al. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif. 2005 23 : 421 8.
46. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molec. Cell. Biol. 1994 14 : 1431 7.
47. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity. J. Leukoc. Biol. 2008 83 : 804 16.
48. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007 178 : 1748 58.
49. Rongvaux A, Shea RJ, Mulks MH et al. B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Europ. J. Immunol. 2002 32 : 3225 34.
50. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005 307 : 426 30.
51. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/preB-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 2007 49 : 237 44.
52. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am. J. Kidney Dis. 2005 45 : 275 80.
53. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circ. 2003 108 : 2154 69.
54. Rigalleau V, Gin H. Carbohydrate metabolism in uremia. Curr. Opin. Clin. Nutr. Metab. Care 2005 8 : 463 9.
55. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J. Clin. Endocrinol. Metab. 1994 78 : 25 9.
56. Dzurik R, Spustova V, Lajdova I. Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: Implications for renal failure. Nephron 1993 65 : 108 10.
57. Krause LM, Traxinger R, Krause AP. Uremia and insulin resistance: N-carbamoyl-asparagine decreases insulin-sensitive glucose uptake in rat adipocytes. Kidney Int. 2004 65 : 881 7.
58. Oimomi M, Hatanaka H, Yoshimura Y, Yokono K, Baba S, Taketomi K. Carbamylation of insulin and its biological activity. Nephron 1987 46 : 63 6.
59. Mak RH. Effects of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J. Pediatr. 1996 129 : 97 104.
60. Mak RH. Intravenous 1,25-dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992 41 : 1049 54.
61. Levi E, Fadda GZ, Thanakitcharu P, Massry SG. Chronology of cellular events leading to derangements in function of pancreatic islets in chronic renal failure. J. Am. Soc. Nephrol. 1992 3 : 1139 46.
62. Gohda T, Gotoh H, Tanimoto M et al. Relationship between abdominal fat accumulation and insulin resistance in hemodialysis patients. Hypertens. Res. 2008 31 : 83 8.
63. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr. Opin. Clin. Nutr. Metab. Care 2005 5 : 377 83.
64. De Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor α produces insulin resistance in skeletal muscle by activation of inhibitor B kinase in a p38 MAPK-dependent manner. J. Biol. Chem. 2004 279 : 17070 78.
65. Gao Z, Zuberi A, Quon MJ, Jianping Y. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor - Treated cells through targeting multiple serine kinases. J. Biol. Chem. 2003 278 : 24944 50.
66. Plomgaard P, Fischer CP, Ibfelt T, Pederse BK, van Hall G. Tumor necrosis factor-α modulated human in vivo lipolysis. J. Clin. Endocrinol. Metab. 2008 93 : 543 9.
67. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB. Diabetes 2002 51 : 2005 11.
68. Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004 279 : 32345 53.
69. Lam TKT, Yoshii H, Haber AH et al. Free fatty acid-induced hepatic insulin resistance: A potential role for protein kinase C. Am. J. Physiol. 2002 283 : E682 91.
70. Boden G, She P, Mozzoli M et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kB pathway in rat liver. Diabetes 2005 54 : 3458 65.
71. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002 51 : 3391 9.
72. Johnston JA. Are SOCS suppressors, regulators, and degraders? J. Leukoc. Biol. 2004 75 : 743 8.
73. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 2000 275 : 15985 91.
74. Mooney RA, Senn J, Cameron S et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. J. Biol. Chem. 2001 276 : 25889 93.
75. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Molec. Cell Biol. 2004 24 : 5434 46.
76. Raj DS, Dominic EA, Pai A et al. Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. Kidney Int. 2005 68 : 2338 44.
77. Abbott WG, Lillioja S, Young AA et al. Relationship between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population. Diabetes 1987 36 : 897 904.
78. Axelsson J, Oureshi AR, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am. J. Clinical Nutrition 2004 80 : 1222 9.